Literature DB >> 9422572

Fraction size and dose parameters related to the incidence of pericardial effusions.

M K Martel1, W M Sahijdak, R K Ten Haken, M L Kessler, A T Turrisi.   

Abstract

PURPOSE: The influence of treatment parameters, such as (a) fraction size and (b) average and maximum dose (as derived from three-dimensional (3D) distributions), on the incidence of pericarditis was analyzed. To understand and predict the dose and volume effect on the pericardium, a normal tissue-complication probability model was tested with these complication data. METHODS AND MATERIALS: Patients (n = 57) entered in 3 consecutive University of Michigan protocols of combined modality for treatment of localized esophageal carcinoma, and having 3D treatment planning for radiation therapy were the subject of this study. Univariate and multivariate analyses were performed to determine the significance of the effect of fraction size and dose parameters on the development of any grade of pericarditis. Dose distributions were corrected for the biological effect of fraction size using the linear-quadratic method. Normal tissue complication probability (NTCP) was calculated with the Lyman model.
RESULTS: Nonmalignant pericardial effusions occurred in 5 of the 57 patients; all effusions were in patients who received treatment with 3.5 Gy daily fractions. On multivariate analysis, no dose factor except fraction size predicted pericarditis, until the dose distributions were corrected for the effect of fraction size ("bio"-dose). Then, both "bio-average" and "bio-maximum" dose were significant predictive factors (p = 0.014). NTCPs for the patients with pericarditis range from 62% to 99% for the calculations with the "bio"-dose distributions vs. 0.5% to 27% for the uncorrected distributions. DISCUSSION: A normal tissue complication probability (NTCP) model predicts a trend towards a high incidence of radiation pericarditis for patients who have high complication probabilities. It is important to correct the dose distribution for the effects of fractionation, particularly when the fraction size deviates greatly from standard (2.0 Gy) fractionation.

Entities:  

Mesh:

Year:  1998        PMID: 9422572     DOI: 10.1016/s0360-3016(97)00584-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  36 in total

1.  Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.

Authors:  Andre Konski; Tianyu Li; Michael Christensen; Jonathan D Cheng; Jian Q Yu; Kevin Crawford; Oleh Haluszka; Jeffrey Tokar; Walter Scott; Neal J Meropol; Steven J Cohen; Alan Maurer; Gary M Freedman
Journal:  Radiother Oncol       Date:  2012-06-07       Impact factor: 6.280

2.  Spanish radiobiological pattern of care in lung cancer: a GOECP/SEOR study.

Authors:  J A González; M Chust; R Delgado; A Gómez; N Rodríguez; M J Ruiz; F Casas
Journal:  Clin Transl Oncol       Date:  2010-04       Impact factor: 3.405

3.  Evaluating inter-campus plan consistency using a knowledge based planning model.

Authors:  Sean L Berry; Rongtao Ma; Amanda Boczkowski; Andrew Jackson; Pengpeng Zhang; Margie Hunt
Journal:  Radiother Oncol       Date:  2016-07-06       Impact factor: 6.280

4.  Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue.

Authors:  Ichinosuke Hyodo
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

Review 5.  Cardiac side effects of conventional and particle radiotherapy in cancer patients.

Authors:  A Wittig; R Engenhart-Cabillic
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

6.  Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT.

Authors:  Stefan Münch; Sylvia Aichmeier; Alexander Hapfelmeier; Marciana-Nona Duma; Markus Oechsner; Marcus Feith; Stephanie E Combs; Daniel Habermehl
Journal:  Strahlenther Onkol       Date:  2016-07-14       Impact factor: 3.621

7.  Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Authors:  Matthew S Ning; Linglong Tang; Daniel R Gomez; Ting Xu; Yangkun Luo; Jinhai Huo; Elie Mouhayar; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-05-22       Impact factor: 7.038

Review 8.  Radiation-Associated Pericardial Disease.

Authors:  Natalie Szpakowski; Milind Y Desai
Journal:  Curr Cardiol Rep       Date:  2019-07-27       Impact factor: 2.931

9.  Esophageal motion during radiotherapy: quantification and margin implications.

Authors:  R J Cohen; K Paskalev; S Litwin; R A Price; S J Feigenberg; A A Konski
Journal:  Dis Esophagus       Date:  2010-01-15       Impact factor: 3.429

10.  Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).

Authors:  M van Heijl; J J B van Lanschot; L B Koppert; M I van Berge Henegouwen; K Muller; E W Steyerberg; H van Dekken; B P L Wijnhoven; H W Tilanus; D J Richel; O R C Busch; J F Bartelsman; C C E Koning; G J Offerhaus; A van der Gaast
Journal:  BMC Surg       Date:  2008-11-26       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.